Printer Friendly

SURVIVAL TECHNOLOGY ANNOUNCES CO-MARKETING AGREEMENT FOR EPIPEN

 SURVIVAL TECHNOLOGY ANNOUNCES CO-MARKETING AGREEMENT FOR EPIPEN
 ROCKVILLE, Md., April 6 /PRNewswire/ -- Survival Technology, Inc. (NASDAQ-NMS: SURV) announced today that Center Laboratories, the licensee for the EpiPen auto-injector for immediate treatment of allergic reactions, has entered an agreement with Fisons Pharmaceuticals to co-promote this potentially life-saving product in the United States.
 Under the terms of the agreement, the Fisons sales force of more than 350 representatives will expand the marketing of EpiPen to include primary care physicians and pediatricians. The Center Laboratories sales force will continue promotion of the product to allergists.
 "We are pleased that this important product should now become available to more patients who need it," said James H. Miller, president and chief executive officer of Survival Technology. He noted that the agreement may result in substantial increases in EpiPen sales in the years ahead.
 EpiPen and EpiPen Jr., developed and produced by Survival Technology, are prescribed to patients at risk of severe allergic reactions to insect stings, foods, drugs and other substances. The pen-like auto-injector permits the immediate self-injection of epinephrine, the drug of choice for emergency treatment of such conditions.
 It has been estimated that up to 15 percent of the population may be predisposed to severe and potentially life-threatening allergic reactions known as anaphylaxis.
 Survival Technology, Inc., is a technology-based health care company that designs, develops and produces automatic injectors, prefilled syringes and medical electronics, with a major focus on safe and convenient participation by the patient in injection therapy. The company also supplies delivery system design, pharmaceutical research and development and sterile product manufacturing to major pharmaceutical companies worldwide.
 -0- 4/6/92
 /NOTE: EpiPen is a registered trademark./
 /CONTACT: Napoleon Monroe, vice president, or Kathleen Austin, marketing assistant, Survival Technology, 301-926-1800/
 (SURV) CO: Survival Technology, Inc.; Center Laboratories; Fisons
 Pharmaceuticals ST: Maryland IN: MTC SU: PDT


TW-DC -- DC017 -- 5399 04/06/92 13:17 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 6, 1992
Words:313
Previous Article:ICN PHARMACEUTICALS REPORTS INCREASE IN NET INCOME AND SALES IN 1991
Next Article:JAMES F. HERRINGTON NAMED VICE PRESIDENT, SALES AND SERVICE AT PEER REVIEW ANALYSIS


Related Articles
SURVIVAL TECHNOLOGY ANNOUNCES SECOND QUARTER RESULTS
SURVIVAL TECHNOLOGY, INC., ANNOUNCES FOURTH QUARTER EARNINGS INCREASE AND FISCAL 1992 AUDITED RESULTS
SURVIVAL TECHNOLOGY, INC. ANNOUNCES 100 PERCENT EARNINGS INCREASE FOR FIRST QUARTER FISCAL 1993
STI STRENGTHENS PRODUCT LINE, GLOBAL REACH TO BETTER POSITION FOR LONG-TERM GROWTH
STI ANNOUNCES FIRST QUARTER EARNINGS
STI ANNOUNCES SECOND QUARTER EARNINGS
Meridian Announces A Nationwide Voluntary Product Exchange of EpiEZPen(R) Auto-Injectors
Meridian Announces Nationwide Voluntary Class I Recall of Epipen(R) And Epipen(R) Jr. Auto-Injectors
Dey And Meridian Respond To Demand For EpiPen(R) and EpiPen Jr.(R) Replacements
Dey and Meridian Pronounce EpiPen(R) Shortage Over in Time for Back-To-School

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters